Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care

Rhea-AI Summary

Medtronic (NYSE:MDT) agreed to acquire Scientia Vascular for $550 million, subject to customary adjustments and potential earn‑outs, to integrate Scientia's guidewires and catheters into Medtronic's neurovascular portfolio.

The deal covers ~310 employees, targets faster access in stroke care, is expected to close in 1H FY27, and is forecast to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter.

Positive

• Acquisition value of $550 million to expand neurovascular offerings
• Adds a comprehensive guidewire and catheter portfolio to Medtronic’s products
• Deal expected to be accretive after FY27, per company guidance

Negative

• Transaction includes potential undisclosed earn‑outs and milestone payments
• Close subject to regulatory approvals and other customary closing conditions
• Expected to be minimally dilutive to adjusted EPS in FY27

News Market Reaction – MDT

-1.59%

1 alert

-1.59% News Effect

On the day this news was published, MDT declined 1.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Acquisition value: $550 million Scientia employees: Approximately 310 employees Annual stroke cases: 12 million people

3 metrics

Acquisition value $550 million Agreed purchase price for Scientia Vascular, subject to adjustments

Scientia employees Approximately 310 employees Scientia Vascular workforce in Salt Lake City, Utah

Annual stroke cases 12 million people Global stroke incidence per year cited in release

Market Reality Check

Price: $89.89 Vol: Volume 10,887,117 is 1.21...

normal vol

$89.89 Last Close

Volume Volume 10,887,117 is 1.21x the 20-day average of 9,005,541, indicating elevated interest ahead of this acquisition news. normal

Technical Shares at $91.34 trade below the 200-day MA of $94.25 and about 14.1% under the 52-week high of $106.33.

Peers on Argus

MDT gained 0.48% with above-average volume while key device peers like SYK, BSX,...

MDT gained 0.48% with above-average volume while key device peers like SYK, BSX, EW, ZBH, and PHG also showed single-day gains. Scanner data did not flag a coordinated sector momentum move, pointing to a company-specific narrative around this neurovascular acquisition.

Previous Acquisition Reports

2 past events · Latest: Feb 03 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	Acquisition announcement	Positive	+0.5%	Intent to acquire CathWorks to add AI-driven coronary physiology platform.
Aug 27	Asset divestiture	Positive	-0.6%	Sale of Paceart Optima system to PaceMate expanding that firm’s reach.

Pattern Detected

Recent acquisition headlines have produced modest, mixed reactions, with one slight gain and one small decline around the news dates.

Recent Company History

Over the past year, Medtronic used M&A both as buyer and seller. On Feb 3, 2026, it agreed to acquire CathWorks for up to $585 million to expand its interventional cardiology portfolio, with a modest 0.46% share gain. Earlier, on Aug 27, 2024, PaceMate acquired Medtronic’s Paceart Optima system, and MDT slipped 0.6%. Today’s Scientia deal continues this portfolio‑shaping strategy, now focused on neurovascular access technologies.

Historical Comparison

-0.1% avg move · Past acquisition-related headlines for MDT produced an average move of -0.07%, suggesting typically ...

acquisition

-0.1%

Average Historical Move acquisition

Past acquisition-related headlines for MDT produced an average move of -0.07%, suggesting typically muted immediate price reactions to M&A news.

Recent deals show Medtronic reshaping its portfolio via acquisitions and divestitures, from CathWorks in interventional cardiology to selling Paceart Optima, with the new Scientia agreement extending this strategy into neurovascular access.

Market Pulse Summary

This announcement details Medtronic’s agreement to acquire Scientia Vascular for $550 million, addin...

Analysis

This announcement details Medtronic’s agreement to acquire Scientia Vascular for $550 million, adding guidewire and catheter technologies aimed at complex neurovascular procedures. The deal targets a large stroke population of about 12 million patients annually and is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter. In context of prior acquisitions and divestitures, it continues Medtronic’s portfolio‑shaping in neuroscience and interventional care.

Key Terms

neurovascular, guidewires, catheters, cerebral vasculature, +4 more

8 terms

neurovascular medical

"critical, innovative technology across the neurovascular portfolio"

Neurovascular describes the blood vessels and circulation that supply the brain, spinal cord and other parts of the nervous system, and the medical devices or treatments that protect or repair them. Investors care because disorders of this system—like strokes or aneurysms—drive demand for specialized drugs, devices and procedures; think of it as the plumbing and roads for the brain, where improvements can reduce risk, cut costs, and create market opportunities.

guidewires medical

"Scientia's portfolio of guidewires and catheters can be seamlessly integrated"

Guidewires are thin, flexible metal wires used by doctors as a pathfinder to steer catheters and other instruments through blood vessels or body passages during minimally invasive procedures. Like the lead rope guiding a vehicle through a narrow tunnel, they determine how easily and safely a procedure can be performed; product quality, reliability and regulatory approval affect clinical adoption, procedure outcomes and therefore sales and risk for medical device investors.

catheters medical

"Scientia's portfolio of guidewires and catheters can be seamlessly integrated"

Flexible tubes inserted into the body to deliver fluids, remove liquids, or provide access to blood vessels and organs; they range from simple temporary tubes to specialized devices used in surgeries or long-term care. Investors care because catheter demand, safety records, regulatory approvals, and device improvements directly affect medical-device sales and liability risk—think of them as essential plumbing for healthcare where reliability and regulation drive market value.

cerebral vasculature medical

"Unlike vessels in many other parts of the body, cerebral vasculature is highly complex"

The cerebral vasculature is the network of arteries, veins and tiny vessels that deliver oxygen and nutrients to the brain and remove waste—think of it as the brain’s highway system for blood. It matters to investors because diseases, injuries or treatments that affect these vessels (for example strokes, aneurysms or blood-clotting issues) drive demand for drugs, devices, diagnostics and care, influence regulatory approvals and clinical trial outcomes, and can materially affect a health-related company’s value.

occlusion medical

"creating significant challenges for physicians attempting to reach the site of an occlusion"

Occlusion is the blocking or closing of a blood vessel or other bodily passage that reduces or stops normal flow—like a kink in a garden hose that prevents water from getting through. For investors, occlusion matters because it is the biological problem many drugs, medical devices and diagnostic tests are designed to treat or detect; its frequency, severity and how well treatments work affect clinical success, regulatory approval, market demand and potential revenue.

microwires medical

""Microwires and microcatheters are required for all neurointerventional cases,""

Microwires are extremely thin metal filaments used as conductive paths or tiny structural parts inside medical devices, sensors and electronic components. They matter to investors because their material, durability and manufacturing quality directly affect a product’s performance, safety, regulatory approval and cost — like the threads in a garment that determine how strong and reliable the finished piece will be.

microcatheters medical

""Microwires and microcatheters are required for all neurointerventional cases,""

A microcatheter is a very thin, flexible tube used by doctors to reach small blood vessels or tight spaces inside the body during minimally invasive procedures, carrying tiny tools, implants, or medication. For investors, microcatheters matter because they enable advanced treatments, drive sales of complementary medical devices and supplies, and can affect regulatory approvals and hospital adoption—like a narrow delivery drone that makes new therapies practical and marketable.

neurointerventional medical

"Microwires and microcatheters are required for all neurointerventional cases"

Neurointerventional describes minimally invasive procedures used to diagnose and treat diseases of the brain, spinal cord and their blood vessels, performed with thin tubes, tiny implants and real‑time imaging instead of open surgery. Investors watch this area because demand, clinical outcomes, regulatory approvals and reimbursement determine sales of specialized devices, imaging systems and hospital services—similar to how a shift from full surgery to keyhole repairs can change costs, recovery times and market opportunities.

AI-generated analysis. Not financial advice.

Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'

GALWAY, Ireland, March 10, 2026 /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.

Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow.

In stroke treatment, every second matters. With each second of restricted blood flow, the brain loses millions of brain cells. Today, stroke is the third leading cause of death and leading cause of disability worldwide. 

Unlike vessels in many other parts of the body, cerebral vasculature is highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.

Scientia's novel access platform is designed to address these challenges by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency.

"Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care," said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic. "This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic's best-in-class therapies, combined with Scientia's leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world." 

"As a company committed to improving patients' lives, we are humbled and excited for what's ahead," said Rick Randall, CEO, Scientia. "Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting."

"Microwires and microcatheters are required for all neurointerventional cases," said Dr. David Fiorella, director of the Cerebrovascular Center at Stony Brook Medicine. "Correspondingly, better microwires and microcatheters make every single case technically easier, faster and ultimately safer for patients. This revolutionary microwire technology has enabled – and will continue to enable – access and simplify the neurovascular procedures we do."

This acquisition is expected to close in the first half of FY27, subject to regulatory approvals and satisfaction of other closing conditions. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.

About the Neurovascular Business at Medtronic 
Medtronic helped create the neurovascular market – introducing innovations like liquid embolic, stent retrievers, and flow diverters. Today, with products covering multiple conditions and disease states, we work to eliminate the burden of stroke and other neurovascular diseases globally by transforming care, one breakthrough at a time. Together with our partners, including physicians, hospitals, governments and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide. For more information, follow Medtronic Neurovascular on LinkedIn.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Erika Winkels	Ingrid Goldberg
Public Relations	Investor Relations
+1-612-558-8932	+1-612-505-2696

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care-302708767.html

SOURCE Medtronic plc

FAQ

What is Medtronic (MDT) acquiring Scientia Vascular for and when will the deal close?

Medtronic is acquiring Scientia Vascular for $550 million, subject to adjustments and potential earn‑outs. According to the company, the transaction is expected to close in the first half of FY27, pending regulatory approvals and closing conditions.

How will the Scientia Vascular acquisition affect Medtronic’s neurovascular product lineup (MDT)?

The acquisition integrates Scientia’s guidewires and catheters into Medtronic’s neurovascular portfolio to provide a full procedural workflow. According to the company, this aims to improve access and simplify neurovascular procedures across hemorrhagic and ischemic stroke care.

What financial impact did Medtronic (MDT) disclose for the Scientia Vascular deal in FY27?

Medtronic said the acquisition is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter. According to the company, the initial dilution is expected to be modest before returning to positive EPS contribution.

How many employees and where is Scientia Vascular based in the Medtronic (MDT) acquisition?

Scientia Vascular operates from Salt Lake City, Utah with approximately 310 employees. According to the company, the team and technology will be integrated to scale access solutions globally through Medtronic’s network.

Are there outstanding contingencies or additional payments tied to Medtronic’s (MDT) purchase of Scientia Vascular?

Yes. The purchase price is $550 million subject to customary adjustments and includes potential undisclosed earn‑out and milestone payments. According to the company, additional contingent payments may occur post‑acquisition based on agreed milestones.